Skip to content

Optical Coherence Tomography of Airway and Pleural Disorders

Optical Coherence Tomography of Airway and Pleural Disorders

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00580892
Enrollment
0
Registered
2007-12-27
Start date
2007-07-31
Completion date
2018-07-31
Last updated
2022-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disorder of Pleura and Pleural Cavity

Brief summary

The researcher can use Optical coherence tomography a near-infrared diode to emit light that can produce images of the specimen under investigation and provide information about tissue abnormalities without causing damage.

Detailed description

The researcher can use Optical coherence tomography endoscopic imaging to improve diagnosis and treatment of airway and pleural malignancy. In the events of burn injury and smoke inhalation injury, the Optical coherence tomography can determine the change of the airway tissues and severity of airway injury. During endoscopic procedure the lesions will be biopsied and prepared by standard histologic methods. The Optical coherence tomography endoscopic imaging can measured histologic of the tissue samples and compared to standard histologic examination. The Optical coherence tomography endoscopic imaging can measured the epithelial thickness and compared to visual inspection of the mucosa on bronchoscopy.

Interventions

Optical Coherence Tomography imaging

Sponsors

Beckman Laser Institute University of California Irvine
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult 18 or older, male or female. * Plans for bronchoscopic with possible biopsy procedures.

Exclusion criteria

* Age less than 18 years of age * Not plan for bronchoscopic with possible biopsy procedures. * Pregnant or breastfeeding.

Design outcomes

Primary

MeasureTime frame
histopathologyup to 4 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026